The current state of hormonal therapy for prostate cancer

被引：296

作者：

Hellerstedt, BA ^{[1
]}

Pienta, KJ ^{[1
]}

机构：

[1] Univ Michigan, Med Ctr, Urol Oncol Program, Ann Arbor, MI USA

来源：

CA-A CANCER JOURNAL FOR CLINICIANS | 2002年 / 52卷 / 03期

关键词：

D O I：

10.3322/canjclin.52.3.154

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Androgen deprivation therapy remains a mainstay of treatment for men with prostate cancer. New uses for hormonal therapy, including use in the adjuvant and neoadjuvant setting, are being evaluated. Prevention of the side effects of therapy has led to the development of alternative schedules and therapeutics.

引用

页码：154 / 179

页数：26

共 105 条

[1] *AG HLTH CAR POL R, 1999, REL EFF COST EFF MET
[2] [Anonymous], 1997, Br J Urol, V79, P235
[3] [Anonymous], 1967, J Urol, V98, P516
[4] DIETHYLSTILBESTROL IN TREATMENT OF POSTORCHIECTOMY VASOMOTOR SYMPTOMS AND ITS RELATIONSHIP WITH SERUM FOLLICLE-STIMULATING-HORMONE, LUTEINIZING-HORMONE, AND TESTOSTERONE
ATALA, A
AMIN, M
HARTY, JI
[J]. UROLOGY, 1992, 39 (02) : 108 - 110
[5] BAILAR JC, 1970, CANCER, V26, P257, DOI 10.1002/1097-0142(197008)26:2<257::AID-CNCR2820260203>3.0.CO
[6] 2-9
[7] BALES GT, 1996, J UROLOGY, V155, pA1069
[8] Cost-effectiveness of androgen suppression therapies in advanced prostate cancer
Bayoumi, AM
Brown, AD
Garber, AM
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (21): : 1731 - 1739
[9] Blackard C E, 1973, Urology, V1, P553, DOI 10.1016/0090-4295(73)90515-3
[10] GOSERELIN ACETATE WITH OR WITHOUT FLUTAMIDE IN THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PROSTATE-CANCER
BOCCARDO, F
PACE, M
RUBAGOTTI, A
GUARNERI, D
DECENSI, A
ONETO, F
MARTORANA, G
GIULIANI, L
SELVAGGI, F
BATTAGLIA, M
DELLIPONTI, U
PETRACCO, S
CORTELLINI, P
ZIVERI, M
FERRARIS, V
BRUTTINI, GP
EPIS, R
COMERI, G
GALLO, G
[J]. EUROPEAN JOURNAL OF CANCER, 1993, 29A (08) : 1088 - 1093

← 1 2 3 4 5 6 7 8 9 10 →